- Home
- HTBI vs PHAR Comparison
HTBI vs PHAR Comparison
Compare HTBI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- PHAR
- Stock Information
- Founded
- HTBI 1926
- PHAR 1988
- Country
- HTBI United States
- PHAR Netherlands
- Employees
- HTBI N/A
- PHAR N/A
- Industry
- HTBI Savings Institutions
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- HTBI Finance
- PHAR Health Care
- Exchange
- HTBI Nasdaq
- PHAR Nasdaq
- Market Cap
- HTBI 641.9M
- PHAR 679.0M
- IPO Year
- HTBI 2012
- PHAR N/A
- Fundamental
- Price
- HTBI $35.02
- PHAR $9.55
- Analyst Decision
- HTBI Buy
- PHAR Strong Buy
- Analyst Count
- HTBI 4
- PHAR 3
- Target Price
- HTBI $39.00
- PHAR $27.00
- AVG Volume (30 Days)
- HTBI 31.9K
- PHAR 5.4K
- Earning Date
- HTBI 01-31-2025
- PHAR 03-13-2025
- Dividend Yield
- HTBI 1.37%
- PHAR N/A
- EPS Growth
- HTBI 14.18
- PHAR N/A
- EPS
- HTBI 3.52
- PHAR N/A
- Revenue
- HTBI $187,440,000.00
- PHAR $285,745,000.00
- Revenue This Year
- HTBI N/A
- PHAR $20.08
- Revenue Next Year
- HTBI N/A
- PHAR $9.22
- P/E Ratio
- HTBI $9.73
- PHAR N/A
- Revenue Growth
- HTBI 2.84
- PHAR 30.64
- 52 Week Low
- HTBI $23.55
- PHAR $6.65
- 52 Week High
- HTBI $38.99
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- HTBI 56.87
- PHAR 50.97
- Support Level
- HTBI $31.11
- PHAR $9.37
- Resistance Level
- HTBI $33.83
- PHAR $10.01
- Average True Range (ATR)
- HTBI 0.84
- PHAR 0.52
- MACD
- HTBI 0.27
- PHAR -0.10
- Stochastic Oscillator
- HTBI 96.90
- PHAR 28.08
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.